Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 14/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 14/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 14/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 14/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 14/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 14/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12331192 | 1.00 | APP (0.51) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12331875 | 0.93 | APP (0.54) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12331649 | 0.87 | APP (0.52) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12331514 | 0.86 | APP (0.45) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14753312 | 0.86 | APP (0.51) | APP | |
| SCHEMBL14753160 | 0.86 | APP (0.45) | APP | |
| SCHEMBL12331593 | 0.86 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12331519 | 0.85 | APP (0.44) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12331135 | 0.85 | APP (0.44) | APPPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14773079 | 0.85 | APP (0.44) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251379-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | CLN6, NLN, ACHE | APP 32/4885PSEN1 7/4885PSEN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.